Literature DB >> 3995682

Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin.

W N Hait, L Grais, C Benz, E C Cadman.   

Abstract

Calmodulin, a ubiquitous calcium-binding protein, has recently been shown to play an important role in cellular proliferation. The calmodulin inhibitors melittin, trifluoperazine, and chlorpromazine inhibited the growth and clonogenicity of human and murine leukemic cells, and their potency reflected their activity as inhibitors of calmodulin. Melittin, which is a far more potent inhibitor of calmodulin activity, was also a more potent inhibitor of cell growth and clonogenicity. The less active phenothiazine metabolite, chlorpromazine sulfoxide, had much less potent cytotoxic activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995682     DOI: 10.1007/bf00258116

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

1.  Characteristics of the cyclic nucleotide phosphodiesterases of normal and leukemic lymphocytes.

Authors:  W N Hait; B Weiss
Journal:  Biochim Biophys Acta       Date:  1977-03-29

2.  Ca2+-dependent regulator. Production and characterization of a monospecific antibody.

Authors:  J R Dedman; M J Welsh; A R Means
Journal:  J Biol Chem       Date:  1978-10-25       Impact factor: 5.157

3.  Damage of cellular functions by trifluoperazine, a calmodulin-specific drug.

Authors:  M Osborn; K Weber
Journal:  Exp Cell Res       Date:  1980-12       Impact factor: 3.905

4.  The stimulation of cyclic nucleotide phosphodiesterase by a Mr 11 500 calcium binding protein from hepatoma.

Authors:  J P MacManus
Journal:  FEBS Lett       Date:  1981-04-20       Impact factor: 4.124

5.  Interaction of various peptides with calmodulin.

Authors:  M Sellinger-Barnette; B Weiss
Journal:  Adv Cyclic Nucleotide Protein Phosphorylation Res       Date:  1984

6.  Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.

Authors:  E Cadman; F Eiferman
Journal:  J Clin Invest       Date:  1979-09       Impact factor: 14.808

7.  Inhibition of growth of C6 astrocytoma cells by inhibitors of calmodulin.

Authors:  G L Lee; W N Hait
Journal:  Life Sci       Date:  1985-01-28       Impact factor: 5.037

8.  Structural similarities between the Ca2+-dependent regulatory proteins of 3':5'-cyclic nucleotide phosphodiesterase and actomyosin ATPase.

Authors:  D M Watterson; W G Harrelson; P M Keller; F Sharief; T C Vanaman
Journal:  J Biol Chem       Date:  1976-08-10       Impact factor: 5.157

9.  Ultrastructural immunocytochemical localization of calmodulin in cultured cells.

Authors:  M C Willingham; J Wehland; C B Klee; N D Richert; A V Rutherford; I H Pastan
Journal:  J Histochem Cytochem       Date:  1983-04       Impact factor: 2.479

10.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

View more
  15 in total

1.  Free calcium and calmodulin levels in acinar carcinoma and normal acinar cells of rat pancreas.

Authors:  J L Chien; J R Warren
Journal:  Int J Pancreatol       Date:  1988-03

2.  Multistage Nanovectors Enhance the Delivery of Free and Encapsulated Drugs.

Authors:  Jonathan O Martinez; Michael Evangelopoulos; Rohan Bhavane; Stefania Acciardo; Francesco Salvatore; Xuewu Liu; Mauro Ferrari; Ennio Tasciotti
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

3.  Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine.

Authors:  W N Hait; S Morris; J S Lazo; R J Figlin; H J Durivage; K White; P E Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.

Authors:  Islam Rady; Imtiaz A Siddiqui; Mohamad Rady; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2017-05-20       Impact factor: 8.679

Review 5.  Applications and evolution of melittin, the quintessential membrane active peptide.

Authors:  Shantanu Guha; Ryan P Ferrie; Jenisha Ghimire; Cristina R Ventura; Eric Wu; Leisheng Sun; Sarah Y Kim; Gregory R Wiedman; Kalina Hristova; Wimley C Wimley
Journal:  Biochem Pharmacol       Date:  2021-09-17       Impact factor: 6.100

6.  Antitumor effects of ketoconazole and trifluoperazine in murine T-cell lymphomas.

Authors:  S Naftalovich; E Yefenof; Y Eilam
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Ruthenium(II)-N-alkyl phenothiazine complexes as potential anticancer agents.

Authors:  Andreja Leskovac; Sandra Petrovic; Tamara Lazarevic-Pasti; Milena Krstic; Vesna Vasic
Journal:  J Biol Inorg Chem       Date:  2018-04-11       Impact factor: 3.358

8.  The antiproliferative properties of tamoxifen and phenothiazines may be mediated by a unique histamine receptor (?H3) distinct from the calmodulin-binding site.

Authors:  L J Brandes; R P Bogdanovic; M D Cawker; R Bose
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Calmodulin is involved in regulation of cell proliferation.

Authors:  C D Rasmussen; A R Means
Journal:  EMBO J       Date:  1987-12-20       Impact factor: 11.598

Review 10.  Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents.

Authors:  David L Brautigan; Caroline Farrington; Goutham Narla
Journal:  Clin Sci (Lond)       Date:  2021-07-16       Impact factor: 6.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.